Table I.
Cohort demographics, divided by those with and without significant adverse events (SigAE) within 7 years’ time.
| Cohort |
no SigAE |
SigAE |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n=319 | %, mean | SD* | n=236 | %, mean | SD | n=83 | %, mean | SD | p- value | |
| Age, mean | 319 | 68.75 | 10.89 | 236 | 68.59 | 10.68 | 83 | 69.19 | 11.52 | 0.670 |
| Gender, male, % | 314 | 92.04 | 83 | 92.77 | 231 | 91.77 | 0.774 | |||
| Caucasian, % | 314 | 80.89 | 231 | 79.65 | 83 | 84.34 | 0.352 | |||
| RF positive, % | 314 | 84.71 | 231 | 84.42 | 83 | 85.54 | 0.807 | |||
| ACPA positive, % | 265 | 81.89 | 193 | 81.87 | 72 | 81.94 | 0.988 | |||
| Tobacco Use | 314 | 231 | 83 | 0.334 | ||||||
| Never | 62 | 19.75 | 50 | 21.65 | 12 | 14.46 | ||||
| Former | 158 | 50.32 | 115 | 49.78 | 43 | 51.81 | ||||
| Current | 94 | 29.94 | 66 | 28.57 | 28 | 33.73 | ||||
| Yrs RA dx and MTX, mean | 314 | 9.37 | 10.84 | 231 | 9.48 | 10.83 | 83 | 9.07 | 10.91 | 0.767 |
| MTX first DMARD | 152 | 52.63 | 62 | 40.79 | 18 | 11.84 | 0.347 | |||
| Deyo Index, mean | 238 | 1.78 | 2.17 | 175 | 1.66 | 2.18 | 63 | 2.10 | 2.15 | 0.176 |
| Glucocorticoid Use, % | 200 | 63.50 | 151 | 60.93 | 49 | 71.43 | 0.185 | |||
| DAS-28, mean | 311 | 3.86 | 1.10 | 229 | 3.85 | 1.14 | 82 | 3.87 | 0.99 | 0.863 |
| HLA-DRB1-SE | 308 | 227 | 81 | 0.018 | ||||||
| 0 copies | 88 | 28.57 | 73 | 32.16 | 15 | 18.52 | ||||
| 1 copy | 154 | 50.00 | 103 | 45.37 | 51 | 62.96 | ||||
| 2 copies | 66 | 21.43 | 51 | 22.47 | 15 | 18.52 | ||||
| MTHFR, rs1801131 | 250 | 185 | 65 | 0.001 | ||||||
| Homo major (AA) | 109 | 43.60 | 93 | 50.27 | 16 | 24.62 | ||||
| Het (AC) | 105 | 42.00 | 71 | 38.38 | 34 | 52.31 | ||||
| Homo minor (CC) | 36 | 14.40 | 21 | 11.35 | 15 | 23.08 | ||||
| MTHFR, rs1801133 | 251 | 186 | 65 | 0.335 | ||||||
| Homo major (CC) | 131 | 52.19 | 92 | 49.46 | 39 | 60.00 | ||||
| Het (CT) | 95 | 37.85 | 74 | 39.78 | 21 | 32.31 | ||||
| Homo minor (TT) | 25 | 9.96 | 20 | 10.75 | 5 | 7.69 | ||||
| FPGS, rs7033913 | 250 | 186 | 64 | 0.173 | ||||||
| Homo major (TT) | 84 | 33.60 | 66 | 35.48 | 18 | 28.13 | ||||
| Het (TC) | 122 | 48.80 | 92 | 49.46 | 30 | 46.88 | ||||
| Homo minor (CC) | 44 | 17.60 | 28 | 15.05 | 16 | 25.00 | ||||
| FPGS, rs10760503 | 250 | 185 | 65 | 0.027 | ||||||
| Homo major (AA) | 79 | 31.60 | 53 | 28.65 | 26 | 40.00 | ||||
| Het (AG) | 128 | 51.20 | 104 | 56.22 | 24 | 92.31 | ||||
| Homo minor (GG) | 43 | 17.20 | 28 | 15.14 | 15 | 23.08 | ||||
| FPGS, rs10106 | 250 | 185 | 65 | 0.046 | ||||||
| Homo major (AA) | 82 | 32.80 | 55 | 29.73 | 27 | 41.54 | ||||
| Het (AG) | 133 | 53.20 | 107 | 57.84 | 26 | 40.00 | ||||
| Homo minor (GG) | 35 | 14.00 | 23 | 12.43 | 12 | 18.46 | ||||
| GGH, rs12548933 | 251 | 186 | 65 | <0.001 | ||||||
| Homo major (AA) | 175 | 69.72 | 138 | 74.19 | 37 | 56.92 | ||||
| Het (AC) | 65 | 25.90 | 37 | 19.89 | 28 | 43.08 | ||||
| Homo minor (CC) | 11 | 4.38 | 11 | 5.91 | 0 | 0.00 | ||||
| GGH, rs7010484 | 242 | 179 | 63 | 0.283 | ||||||
| Homo major (TT) | 103 | 42.56 | 80 | 44.69 | 23 | 36.51 | ||||
| Het (TC) | 110 | 45.45 | 76 | 42.46 | 34 | 53.97 | ||||
| Homo minor (CC) | 29 | 11.98 | 23 | 12.85 | 6 | 9.52 | ||||
| GGH, rs4617146 | 249 | 184 | 65 | 0.865 | ||||||
| Homo major (CC) | 168 | 67.47 | 124 | 67.39 | 44 | 67.69 | ||||
| Het (CT) | 72 | 28.92 | 54 | 43.55 | 18 | 27.69 | ||||
| Homo minor (TT) | 9 | 3.61 | 6 | 3.26 | 3 | 4.62 | ||||
| GGH, rs719235 | 251 | 186 | 65 | 0.331 | ||||||
| Homo major (GG) | 138 | 54.98 | 99 | 53.23 | 39 | 60.00 | ||||
| Het (GT) | 96 | 38.25 | 72 | 38.71 | 24 | 36.92 | ||||
| Homo minor (TT) | 17 | 6.77 | 15 | 8.06 | 2 | 3.08 | ||||
| GGH, rs11988534 | 251 | 186 | 65 | 0.276 | ||||||
| Homo major (CC) | 141 | 0.56 | 110 | 59.14 | 31 | 47.69 | ||||
| Het (CT) | 90 | 35.86 | 62 | 33.33 | 28 | 43.08 | ||||
| Homo minor (TT) | 20 | 7.97 | 14 | 7.53 | 6 | 9.23 | ||||
*
SD: standard deviation; RF: rheumatoid factor; ACPA: anti-citrullinated protein antibody; Yrs RA dx and MTX: years between rheumatoid arthritis diagnosis and methotrexate course; MTX: methotrexate; DMARD: disease-modifying anti-rheumatic drug; DAS-28: 28 joint 4-variable disease activity score; HLA-DRB1-SE: major histocompatibility complex, class II, DR beta 1 shared epitope, high-risk for rheumatoid arthritis; MTHFR: methylenetetrahydrofolate reductase; FPGS: folypoly-gamma-glutamate synthetase; GGH: gamma-glutamyl hydrolase; ACPA: anti-citrullinated protein antibody; homo: homozygous; het: heterozygous